Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics, Inc. (NASDAQ: ADMA) is a U.S.-based, end-to-end commercial biopharmaceutical company focused on specialty plasma-derived biologics and other specialty biologics for immunodeficient patients and individuals at risk for certain infectious diseases. The ADMA news feed on Stock Titan aggregates company-issued updates and market-moving announcements so readers can follow developments affecting the ADMA stock and its underlying business.
In its press releases, ADMA regularly reports on quarterly and annual financial results, including total revenue, GAAP net income, adjusted EBITDA and adjusted net income, as well as updates to its financial guidance. The company also issues news on operational milestones such as U.S. Food and Drug Administration (FDA) approvals for its production processes, progress with its yield enhancement production technology, and expansion of its U.S.-based manufacturing and plasma collection infrastructure.
Investors following ADMA news can expect coverage of commercial trends for its FDA-approved plasma-derived products ASCENIV, BIVIGAM and NABI-HB, including reported demand dynamics, payer coverage discussions, and distribution agreements. The company’s updates also address pipeline progress for SG-001, a pre-clinical hyperimmune globulin targeting Streptococcus pneumoniae, along with commentary on intellectual property, supply chain strategy and capital structure actions such as debt refinancing and share repurchase authorizations.
This news page is useful for tracking how ADMA communicates its financial outlook, operational initiatives and product performance over time. Readers interested in the ADMA stock can use the curated news flow to monitor earnings releases, regulatory and manufacturing updates, and other disclosures that the company furnishes through press releases and related filings.
ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in several investor conferences in September 2020. The events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 2:30 p.m. ET, Cantor Virtual Global Healthcare Conference on September 17 at 11:20 a.m. ET, and Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on September 22 at 9:10 a.m. ET. Webcasts will be available on ADMA's website and archived for 90 days.
ADMA Biologics reported $18 million in total revenues for the first half of 2020, reflecting a 78% increase year-over-year. Despite a 19% revenue growth in Q2 compared to 2019, the company faced disruptions due to COVID-19, affecting product testing and supply chains. ADMA opened a new plasma center and joined the CoVIg-19 Plasma Alliance. It anticipates generating $250 million in annual revenue within three to five years. However, net loss for Q2 reached $20.2 million, up from $13.2 million in Q2 2019, driven by increased operational costs.
ADMA Biologics, Inc. (ADMA) announced a live conference call scheduled for August 5, 2020, at 4:30 p.m. ET to discuss its business highlights and financial results for Q2 2020, ending June 30, 2020. The call can be accessed via phone or through an audio webcast available on ADMA's investor relations website. The company is focused on manufacturing and developing plasma-derived biologics targeting immunodeficient patients.
ADMA Biologics announced the opening of its second plasma collection facility, ADMA BioCenters, in Knoxville, TN. This facility is part of ADMA's plan to establish 5 to 10 new centers by the end of 2022. A Biologics License Application (BLA) has been submitted to the FDA for approval, expected by mid-2021. The Knoxville center features modern equipment and amenities to enhance donor experience. Until FDA approval, ADMA can collect plasma, which will then be used for production of its FDA-approved immunoglobulin products.
ADMA Biologics announced the approval of Martha J. Demski's election to its Board of Directors during the Annual Shareholder Meeting on June 18, 2020. Ms. Demski brings over 35 years of biotechnology experience, previously serving as CFO at Ajinomoto Althea and holding positions at Vical and the Sidney Kimmel Cancer Center. Her financial expertise is expected to bolster ADMA's growth, especially with products like BIVIGAM and ASCENIV. ADMA is focused on expanding its plasma collection facilities and developing novel immunoglobulin products for immunodeficient patients.
ADMA Biologics (ADMA) announced key corporate achievements aimed at improving its supply chain and production capacity. The company successfully manufactured three BIVIGAM® conformance batches at a larger plasma volume, anticipates quicker market turnaround, and has installed a new aseptic filling machine to enhance production capabilities. These initiatives are expected to streamline operations and reduce costs, aligning with ADMA's objectives for 2020. Additionally, construction is underway for new plasma collection centers in Tennessee, further supporting their production needs.
Summary not available.